Reducing irinotecan-associated diarrhea in children
- PMID: 17570704
- DOI: 10.1002/pbc.21280
Reducing irinotecan-associated diarrhea in children
Abstract
Irinotecan is increasingly being used in pediatric oncology. Amelioration of diarrhea associated with protracted irinotecan administration may reduce morbidity and improve dose intensity. In this review, we discuss what is known about the pathogenesis of this toxicity as well as potential predisposing genetic factors. We comprehensively summarize the literature regarding available prevention and treatment strategies, and report data on the use of cephalosporin prophylaxis in 51 patients treated on various pediatric trials. This approach is feasible in children and allows for tolerance of higher doses of protracted irinotecan.
(c) 2007 Wiley-Liss, Inc.
Comment in
- 
  
  How can we ameliorate irinotecan-associated diarrhea in children with poor compliance for oral cephalosporin?Pediatr Blood Cancer. 2009 Jan;52(1):145. doi: 10.1002/pbc.21739. Pediatr Blood Cancer. 2009. PMID: 18798559 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
- Medical
 
        